Observational studyBMJ open2019
Prostate cancer with bone metastasis in Beijing: an observational study of prevalence, hospital visits and treatment costs using data from an administrative claims database.
Observational study in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A Systematic Review of the Economic Burden of Prostate Cancer: Direct and Indirect Cost Perspectives.PharmacoEconomics · 2026Pooled it
- Cost Drivers and Financial Burden for Cancer-Affected Families in China: A Systematic Review.Current oncology (Toronto, Ont.) · 2023Pooled it
- ExPeCT: a randomised trial examining the impact of exercise on quality of life in men with metastatic prostate cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Trial
- Article
- Prostate cancer in China: epidemiological trends, genomic insights, and future directions for optimized management.Journal of the National Cancer Center · 2025Review
- The diagnostic value of inflammatory markers in bone metastasis of prostate cancer at initial prostate biopsy.Frontiers in oncology · 2025Article
- Diagnostic Ability of Quantitative Parameters of Whole-Body Bone SPECT/CT Using a Full-Ring 360° Cadmium-Zinc-Telluride Camera for Detecting Bone Metastasis in Patients with Prostate Cancer.Diagnostics (Basel, Switzerland) · 2024Article
- Measurements of peri-prostatic adipose tissue by MRI predict bone metastasis in patients with newly diagnosed prostate cancer.Frontiers in oncology · 2024Article
- Imaging signs and the qualitative diagnosis of solitary rib lesions usingQuantitative imaging in medicine and surgery · 2023Article
- Use of real world data to improve drug coverage decisions in China.BMJ (Clinical research ed.) · 2023Article
- Skull metastasis is a poor prognostic factor for prostate cancer patients with bone metastasis: a retrospective study based on a Chinese population.BMC urology · 2023Article
- Construction and validation of web-based nomograms for detecting and prognosticating in prostate adenocarcinoma with bone metastasis.Scientific reports · 2022Article
- AMPK's double-faced role in advanced stages of prostate cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Concomitant Medication Use With Xiyanping Injection and the Risk of Suspected Allergic Reactions: A Nested Case-Control Study Based on China's National Medical Insurance Database.Frontiers in pharmacology · 2022Article
- CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.Molecular medicine reports · 2022Article
- Factors predicting biochemical response and survival benefits following radioligand therapy with [European journal of nuclear medicine and molecular imaging · 2021Review
- Observational
- Establishment and validation of a novel predictive model to quantify the risk of bone metastasis in patients with prostate cancer.Translational andrology and urology · 2021Article
- Targeted p21 activation by a new double stranded RNA suppresses human prostate cancer cells growth and metastasis.American journal of translational research · 2020Article
- Health Care Utilization and Costs of Patients With Prostate Cancer in China Based on National Health Insurance Database From 2015 to 2017.Frontiers in pharmacology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo estimate the prevalence of prostate cancer with bone metastasis in Beijing, and to estimate hospital visits and direct treatment costs among male urban employees with the disease in Beijing.
designCross-sectional observational study. SETTING AND
participantsPatients with prostate cancer and bone metastasis from the Urban Employee Basic Medical Insurance database covering the employed population of Beijing, China, from 2011 to 2014. PRIMARY AND SECONDARY OUTCOME MEASURES: Prevalence, treatment costs and healthcare visits of patients with prostate cancer and bone metastasis.
resultsA total of 1672 individuals were identified as having prostate cancer. Of these, 737 (44.1%) had bone metastasis, and among these, this was already present at the time of initial prostate cancer diagnosis in 27.0% (199/737). Mean age was 74.6 years (SD ±9.1). Prevalence of prostate cancer with bone metastasis increased from 5.3 per 100 000 males in 2011 to 8.3 per 100 000 males in 2014. The total annual health expenditure per patient (in 2014 American dollars) during the study period was $15 772.1 (SD=$16 942.6) ~$18 206.3 (SD=$18 700.2); 88% of these costs were reimbursed by insurance. Medication accounted for around 50% of total healthcare costs. Western drugs accounted for over 80% of medical costs with endocrine therapy being the most commonly prescribed treatment. There was an average 6.7% increase in expenditure related to diagnostical and therapeutical procedures over study years.
conclusionsThe increase in the prevalence of prostate cancer with bone metastasis and associated healthcare costs in China reveals the growing clinical and economical burden of this disease. The high prevalence of bone metastasis among patients with prostate cancer seen in our study suggests that efforts may be needed to improve symptoms awareness and promote early help-seeking behaviour among the Chinese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.